|Podcasts|November 17, 2011
Parexel's Ethnobridging Expert Discusses Its Importance as a Development Strategy
Advertisement
Parexel’s Ethnobridging Expert Discusses Its Importance as a Development Strategy
Stan Jhee, PharmD, Senior Director of Research, Early Phase at Parexel, defines the importance of ethnobridging in clinical trials, and how it works as a drug development strategy for pharmaceutical companies.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework
2
How the FDA’s CNPV Program Is Reshaping Trial Operations and Accelerated Review Strategies
3
Voyxact Lands FDA Accelerated Approval Following Positive Results in Phase III VISIONARY Trial
4
Drug Repurposing Through AI-Driven In-Silico Clinical Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
